Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Current management strategies for severe and recurrent epistaxis secondary to Hereditary
hemorrhagic telangiectasia (HHT) include surgical procedures, and uncomfortable nasal
packing, both of which are often only short-term solutions. Floseal® may provide a
non-invasive and less painful treatment option for epistaxis in HHT patients. This hemostatic
agent has been shown to be an effective intraoperative hemostatic agent in a number of
surgical procedures including endoscopic sinus surgery. It has also been shown to be
favorable over nasal packing at controlling acute anterior epistaxis. Though the efficacy of
using Floseal® for epistaxis in HHT patients has been proven anecdotally in the literature it
has yet to be proven in a prospective clinical trial. The results of this pilot study will
provide insight into the efficacy of using Floseal® in the management of severe epistaxis in
HHT patients and to assist in the development of a full-scale prospective clinical trial.
Phase:
N/A
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto